Study wrapper · #1101
Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.
Venerito V, Lopalco G, Colaprico C, et al. RMD open. 2026.
DOI: 10.1136/rmdopen-2026-006830PubMed: 42532547
Editor's note
This propensity score-matched study associates concurrent tirzepatide and biologic initiation with improved disease-activity and patient-reported outcomes in obese psoriatic arthritis. With only 31 treated patients and a matched-control rather than randomized design, the findings are promising but should be regarded as preliminary.
Plain-language abstract
In obese patients with psoriatic arthritis, starting tirzepatide alongside biologic therapy was associated with greater weight loss, lower inflammation, and better patient-reported outcomes at 6 months compared with biologics alone. The small sample and non-randomized design temper the conclusions.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026